Who
Sandra Milligan
Director
Company insider
Files Form 4 as: Director, Gossamer Bio; Director, Spyre Therapeutics; Interim CEO, Aspira Women's Health; Head of Research & Development, Organon & Co.
In numbers
- Trades disclosed
- 64
- Buys
- 2
- Sells
- 0
- Bought
- $75K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 2 Jun 2021
- Last trade
- 23 Sep 2026
- Last filed
- 25 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 25 Sep 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,026 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,026 at $0.00 | filing |
| 19 Aug 2025filed 20 Aug 2025 | GOSS Gossamer BioBiotechnology | SEC FORM 4 Bought | $50K26,050 at $1.92 | filing |
| 25 Jun 2025filed 26 Jun 2025 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 8 Jan 2025filed 29 Jan 2025 | Aspira Women's Health | SEC FORM 4 Code F | $4,4496,356 at $0.70 | filing |
| 31 Dec 2024filed 29 Jan 2025 | Aspira Women's Healthoption or derivative | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 31 Dec 2024filed 29 Jan 2025 | Aspira Women's Health | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 31 Dec 2024filed 8 Jan 2025 | Aspira Women's Healthoption or derivative | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 31 Dec 2024filed 8 Jan 2025 | Aspira Women's Health | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 12 Nov 2024filed 13 Nov 2024 | Aspira Women's Healthoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 28 Oct 2024filed 28 Oct 2024 | Aspira Women's Healthoption or derivative | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 6 Jun 2024filed 6 Jun 2024 | GOSS Gossamer Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 14 May 2024filed 16 May 2024 | SYRE Spyre Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,980 at $0.00 | filing |
| 3 May 2024filed 6 May 2024 | Aspira Women's Healthoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 15 Nov 2023filed 17 Nov 2023 | GOSS Gossamer BioBiotechnology | SEC FORM 4 Bought | $25K32,000 at $0.79 | filing |
News
Chardan Capital Begins Coverage on Gossamer Bio (NASDAQ:GOSS)GOSS · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Sandra Milligan; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.